Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Tuesday, up 6.40% from the previous trading day, before settling in for the closing price of $9.38. Over the past 52 weeks, AMLX has traded in a range of $2.08-$9.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -78.71% over the past five years. While this was happening, its average annual earnings per share was recorded 59.36%. With a float of $66.52 million, this company’s outstanding shares have now reached $89.16 million.
Let’s look at the performance matrix of the company that is accounted for 123 employees.
Amylyx Pharmaceuticals Inc (AMLX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 25.40%, while institutional ownership is 84.76%. The most recent insider transaction that took place on Aug 13 ’25, was worth 125,046. In this transaction Chief Legal Officer of this company sold 15,000 shares at a rate of $8.34, taking the stock ownership to the 156,969 shares. Before that another transaction happened on Aug 12 ’25, when Company’s Chief Legal Officer sold 15,000 for $8.07, making the entire transaction worth $121,102. This insider now owns 171,969 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.07 earnings per share (EPS), lower than consensus estimate (set at -0.92) by -0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.80% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 8.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.43 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) saw its 5-day average volume 1.78 million, a positive change from its year-to-date volume of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 89.00%.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 99.85%, which indicates a significant increase from 99.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.55 in the past 14 days, which was higher than the 0.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.85, while its 200-day Moving Average is $5.17. Nevertheless, the first resistance level for the watch stands at $10.26 in the near term. At $10.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.11. If the price goes on to break the first support level at $9.42, it is likely to go to the next support level at $8.86. Assuming the price breaks the second support level, the third support level stands at $8.58.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 889.89 million has total of 89,167K Shares Outstanding. Its annual sales at the moment are 87,370 K in contrast with the sum of -301,740 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -41,440 K.
